Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. It was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company's lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/01/18 | $30,000,000 | Series A |
Aceras Life Sciences F-Prime Capital Partners  OrbiMed Advisors Osage University Partners | undisclosed |
